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Protein Kinase R (PKR) inhibits translation initiation following double-stranded RNA (dsRNA) binding
and thereby represses viral replication. Human cytomegalovirus (HCMV) encodes two noncanonical
dsRNA binding proteins, IRS1 and TRS1, and the expression of at least one of these PKR antagonists is
essential for HCMV replication. In this study, we investigated the role of dsRNA binding by TRS1 in PKR
inhibition. We found that puriﬁed TRS1 binds speciﬁcally to dsRNA with an afﬁnity lower than that of
PKR. Point mutants in the TRS1 dsRNA binding domain that were deﬁcient in rescuing the replication of
vaccinia virus lacking its PKR antagonist E3L were unable to bind to dsRNA but retained the ability bind
to PKR. Thus TRS1 binding to dsRNA and to PKR are separable. Overall, our results are most consistent
with a model in which TRS1 binds simultaneously to both dsRNA and PKR to inhibit PKR activation.
& 2013 Elsevier Inc. All rights reserved.Introduction
Double-stranded RNA (dsRNA) is a pathogen associated mole-
cular pattern commonly associated with viral infection (Weber
et al., 2006). Cytoplasmic or extracellular dsRNA is detected by the
host cell pattern recognition receptors TLR3, RIG-I, and MDA5,
which stimulate the production of interferon and interferon-
stimulated genes (Alexopoulou et al., 2001; Kato et al., 2006;
Yoneyama et al., 2004). Several interferon stimulated genes,
including protein kinase R (PKR), are activated by dsRNA and
establish an antiviral response in the infected host cell.
Activated PKR phosphorylates eIF2α and inhibits translation
initiation by preventing the formation of eIF2–tRNAiMet–GTP
ternary complex (Garcia et al., 2006). Since viruses depend on
the host translation machinery for protein synthesis, PKR activa-
tion has the potential to inhibit viral replication. Viruses have
evolved a variety of strategies to antagonize the PKR pathway,ll rights reserved.
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Fairview Ave N, MS C2–023,including degradation of PKR and the expression of RNA inhibitors
of PKR activation, eIF2α pseudosubstrates, or dsRNA binding
proteins (dsRBPs) (Langland et al., 2006). Viral dsRBPs can seques-
ter dsRNA to prevent PKR activation but also frequently interact
directly with PKR to inhibit its function (Hakki et al., 2006;
Romano et al., 1998; Tan and Katze, 1998).
Many cellular and viral dsRBPs utilize a canonical dsRNA
binding motif, which is characterized by an αβββα fold, to bind
dsRNA (Kharrat et al., 1995). However, several dsRNA-binding viral
PKR antagonists, such as inﬂuenza NS1 (Wang et al., 1999), herpes
simplex US11 (Khoo., 2002), and human cytomegalovirus (HCMV)
IRS1 and TRS1 (Marshall et al., 2009), do not appear to use this
structural motif. IRS1 and TRS1 are members of the viral US22
gene family, which is unique to betaherpesviruses, and have no
obvious homology to other dsRNA binding proteins found outside
of this family. Analyses of truncations and deletions of TRS1 have
mapped a minimal dsRNA binding domain to the US22 domain,
which is found in N-terminal third of TRS1 (Hakki and Geballe,
2005). The C-terminal end of TRS1, which is dispensable for dsRNA
binding, is required for TRS1 to bind and antagonize PKR (Hakki
et al., 2006).
While studies of truncation mutants suggest that dsRNA bind-
ing is necessary but not sufﬁcient for TRS1 to function as a PKR
antagonist, our understanding of the mechanism by which TRS1
binds dsRNA and the relative importance of dsRNA and PKR
C.J. Bierle et al. / Virology 442 (2013) 28–37 29binding by TRS1 remains incomplete. To address these issues, we
investigated the dsRNA binding properties of TRS1. We observed
that TRS1 binds to dsRNAs as short as 20 base pairs. Although its
afﬁnity for dsRNA is lower than that of PKR, TRS1 is more
abundant than PKR in HCMV infected cells at late times post
infection. Our analyses of TRS1 dsRNA binding domain mutants
suggest that while TRS1 binds to PKR and dsRNA using separate
interaction surfaces, TRS1's ability to inhibit PKR likely requires at
least some ability to bind to dsRNA. Together with previous
results, these new data support a model in which TRS1 must
simultaneously bind to both PKR and dsRNA to fully inhibit PKR
activation.Results
Expression and puriﬁcation of TRS1
TRS1 lacks homology to the canonical dsRNA binding motif or
any other structurally characterized dsRNA binding fold (Ramos
et al., 2000). Nonetheless, TRS1 expressed in mammalian cells or
using rabbit reticulocyte lysate binds to the synthetic dsRNA
analogue poly I:C (Child et al., 2012; Hakki and Geballe, 2005).
As TRS1 was present as part of a complex mixture in these binding
assays, it was possible that TRS1's apparent dsRNA binding activity
was mediated by protein–protein interactions between TRS1 and a
cellular dsRNA binding protein. Thus, to test whether TRS1 inter-
acts directly with dsRNA independent of other proteins, we sought
to purify TRS1 for use in dsRNA binding assays.
After unsuccessful attempts to express useful quantities of
soluble protein using codon-optimized TRS1 genes in either
Eschericia coli or Saccharomyces cerevisiae, we engineered recom-
binant baculoviruses that expressed His-tagged TRS1 using either
the HCMV gene or a yeast codon-optimized synthetic TRS1 gene
(Child et al., 2012). Both baculoviruses expressed TRS1, but the
baculovirus encoding the HCMV gene yielded more TRS1 protein
and was thus used in further studies (data not shown). After
optimizing infection and nickel afﬁnity puriﬁcation protocols, we
obtained pure TRS1 and found that it interacted with poly I:C
conjugated beads but not control agarose beads (Fig. 1). PKR
puriﬁed from E. coli using established protocols (Conn, 2003) also
speciﬁcally interacted with poly I:C beads, while an impurity in
this sample bound to the naked control beads. Thus like PKR, TRS1
interacts directly with dsRNA.
Characterization of TRS1–dsRNA binding by electrophoretic mobility
shift assay
We next assessed the dsRNA substrate speciﬁcity and binding
afﬁnity of TRS1 to evaluate whether TRS1 might be able toFig. 1. Puriﬁed TRS1 binds dsRNA. TRS1 puriﬁed from baculovirus infected insect
cells, PKR puriﬁed from bacteria, and BSA were incubated in the presence of poly[I:
C] conjugated and control agarose beads. The input (In) lane contains 10% (150 ng)
of the protein used in each binding reaction. Proteins were visualized by coomassie
blue staining. Bands corresponding to TRS1 and PKR are indicated, while (n)
denotes an impurity in the PKR preparation.compete with PKR for dsRNA binding. Using an electrophoretic
mobility shift assay (EMSA) (Ryder et al., 2008), we found that
pure TRS1 bound to a 29 base pair (bp) long hairpin RNA. Addition
of an equal or greater mass of cold competitor poly I:C to EMSA
binding reactions reduced TRS1 binding to the hairpin RNA (Fig. 2)
while neither free poly C nor tRNA, even at a 30-fold excess,
affected the interaction between TRS1 and dsRNA. These results
provide further evidence that TRS1 binds speciﬁcally to dsRNA.
Next, we incubated RNA hairpins 20, 29, and 39 bp in length
with TRS1 at ﬁnal concentrations between 10 and 1000 nM
(Fig. 3A) (Bevilacqua and Cech, 1996). TRS1 bound to all three
dsRNAs, although with a higher afﬁnity to the 29 and 39 bp
hairpins than to the 20 bp hairpin. We calculated the dissociation
constant (Kd) of TRS1 for the dsRNAs by plotting the fraction of
RNA bound against the TRS1 concentration in the binding reaction
and ﬁtting the binding curve by nonlinear least-squares regression
(Fig. 3C) (Ryder et al., 2008). TRS1 bound to the 20, 29, and 39 bp
dsRNAs with Kds of approximately 440, 230, and 260 nM,
respectively.
PKR binds to and is activated by duplexed RNAs at least 30 bp
in length through cooperative interactions between its two
dsRBDs (Manche et al., 1992). To directly compare the dsRNA
binding activity of PKR to that of TRS1, we expressed and puriﬁed
active PKR from E. coli and subjected it to EMSA using the same
assay conditions used to measure TRS1 binding afﬁnity (Fig. 3B).
Under these conditions, PKR bound to 39 bp dsRNAs with a Kd of
approximately 90 nM (Fig. 3C). This result is within the wide range
of afﬁnities of PKR for dsRNA reported in the literature (from
∼2 nM to 900 nM), which depend on the salt and other assay
conditions (Lemaire et al., 2008; McCormack and Samuel, 1995;
Schmedt et al., 1995). Our results reveal that TRS1 binds speciﬁ-
cally to dsRNA, albeit with a weaker afﬁnity than PKR for compar-
able substrates.Quantiﬁcation of TRS1 and PKR during HCMV infection
Because TRS1 binds dsRNA at a lower afﬁnity than PKR, it
would be unlikely to be able to bind and sequester free dsRNA
away from PKR if the proteins were present at comparable
concentrations during infection. While we have previously char-
acterized the kinetics of dsRNA accumulation during HCMV infec-
tion (Marshall et al., 2009), we have not evaluated the relative
concentrations of PKR and its HCMV antagonists, TRS1 and IRS1,
during infection To estimate these concentrations, we prepared
lysates from mock infected ﬁbroblasts (HFs) and HFs infected with
HCMV[Towne] at an MOI of 3. The relative expression of TRS1, IRS1
and PKR was assessed by immunoblot assays of the lysates
harvested at 2, 8, 24, 48, 72, and 96 h post infection (Fig. 4). Note
that our TRS1 antiserumwas generated using a region of TRS1 thatFig. 2. TRS1 speciﬁcally binds to dsRNA. Native gel shift experiment using 32P
labeled 29 bp hairpin RNA, puriﬁed TRS1, and cold competitor poly C, poly I:C, or
tRNA at concentrations ranging from 1 to 30 fold of that of the radiolabeled probe.
Unbound RNA (UB) and TRS1–RNA complexes (B) are indicated by the arrow and
bar, respectively.
Fig. 3. TRS1 binds dsRNAs as short as 20 bp. Native gel shift experiments using 32P labeled hairpin RNAs 20, 29, or 39 bp in length that were incubated with increasing
quantities of puriﬁed TRS1 (A) or PKR (B) prior to separation by TBE-PAGE. The gels were visualized by phosphorimaging and the fraction of the total RNA hairpin that was
protein-bound (indicated by the bar) was plotted and binding curves calculated using nonlinear least-squares ﬁt regression (C).
Fig. 4. TRS1 and PKR abundance during HCMV infection. HFs were infected with HCMV at a MOI of 3 or were mock infected. Cell lysates prepared at the indicated hour post
infection (HPI), along with the indicated quantities of puriﬁed TRS1 or PKR (left panels), were separated by SDS-PAGE and visualized by immunoblot with antibodies against
TRS1, Actin, or PKR. The intensities of the bands corresponding to full-length TRS1, IRS1, and PKR were compared with the puriﬁed protein controls to estimate protein
abundance and the molar ratios of the viral and cellular proteins present during infection.
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puriﬁed TRS1 or PKR were included on the immunoblots. The
intensity of bands corresponding to TRS1, IRS1, or PKR observed
during HCMV infection from multiple exposures of the immuno-
blot were compared with the puriﬁed protein standards to
estimate the protein concentration and the molar ratio of full
length TRS1 plus IRS1 to PKR at each time point. The molar
concentration of TRS1 and IRS1 were at least 10 fold higher than
PKR at 24 h post infection and later. dsRNA has been detected in
HCMV infected cells at these time points (Marshall et al., 2009).
Similar results were observed in HFs infectioned with HCMV
[AD169] (data not shown).We detected short immunoreactive TRS1 or IRS1 fragments
throughout the infection. At 2 and 8 h post infection, these
fragments were more abundant than the full length proteins.
Whether they are alternatively processed or degraded TRS1/IRS1
remains unclear. Because the antiserum used in to detect TRS1 and
IRS1 is speciﬁc to their N-termini, these fragments are not the
previously described alternative form of IRS1, IRS1263 (Blankenship
and Shenk, 2002). Additionally, these bands were not detected
during HCMV[ΔI/ΔT] infection of normal ﬁbroblasts, indicating
that they are likely not the result of antibody cross-reactivity
(Marshall et al., 2009). Whether these fragments have a biologic
role during infection remains unclear. In conclusion, TRS1 is more
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during HCMV infection (Marshall et al., 2009). Therefore, despite
its lower afﬁnity for dsRNA compared to that of PKR, these data
cannot rule out the possibility that TRS1 is able to compete with
PKR for binding to free dsRNA due to its greater abundance.
Modiﬁcation of TRS1 arginines disrupts dsRNA binding
Identifying TRS1 point mutants deﬁcient in dsRNA binding
would allow us to test whether the PKR–TRS1 interaction is
mediated by dsRNA binding and whether PKR binding by TRS1
could be sufﬁcient to inhibit the activation of PKR. Disruption of
either TRS1's dsRNA (Hakki and Geballe, 2005) or PKR (Hakki et al.,
2006) binding activities by truncating the protein was previously
reported to result in TRS1 that is incapable of antagonizing the PKR
pathway, as measured by rescue of vaccinia lacking its antagonist
E3L (VVΔE3L). These results suggested that neither dsRNA nor PKR
binding by TRS1 is sufﬁcient to inhibit PKR and has led us to
hypothesize that the activity of TRS1 against PKR depends on the
formation of a trimolecular complex consisting of TRS1, PKR, and
dsRNA. However, interpreting these analyses is complicated by our
limited knowledge of the TRS1 protein structure and by the
potential of truncations to severely disrupt the protein's structure.
Charged amino acids often are found on the surface of proteins
and play a role in protein–protein or protein–nucleic acid interac-
tions; mutating these residues is unlikely to disrupt protein
structure (Chothia, 1976). Since arginine is the most numerically
abundant basic amino acid in TRS1, we tested the effect of covalent
modiﬁcation of arginines on TRS1 dsRNA binding. p-hydroxyphe-
nylglyoxal (HPG) reacts with the guanidino group of arginine
residues and has been used to test the effect of selective modiﬁca-
tion of arginine on protein–protein and protein–nucleic acid
interactions (Carven and Stern, 2005; McKee et al., 2009;
Mendoza and Vachet, 2009). We incubated puriﬁed TRS1 or PKR
with increasing concentrations of HPG either before (Fig. 5A) orFig. 5. dsRNA binding can be inhibited by HPG treatment. Puriﬁed TRS1 or PKR was
treated with increasing quantities of p-hydroxyphenylglyoxal as described in
Materials and Methods either before (A) or after (B) incubation and pull-down
with poly I:C agarose beads. Binding was visualized by either α-His or α-PKR
immunoblot. Input (In) lanes contain 10% of the protein used in the binding
reactions.after (Fig. 5B) binding to poly I:C agarose. HPG modiﬁcation of
either TRS1 or PKR prior to incubation with poly I:C beads
prevented their association with the beads. Surprisingly, when
the proteins were ﬁrst bound to the beads and then subjected to
HPG modiﬁcation, TRS1 remained bound while PKR did not. This
may reﬂect differences in the accessibility of the arginine residues
in the dsRNA binding domains or in dynamics of the interaction of
the two proteins with the dsRNA. Regardless, these results suggest
that arginine residues play an important role in dsRNA binding
by TRS1.
Site-directed mutagenesis of TRS1
To better understand the role of dsRNA binding in TRS1's
antagonism of PKR, we next sought to identify a TRS1 point
mutant deﬁcient for dsRNA binding. Knowing both that arginine
residues are involved in dsRNA binding and the approximate
boundaries of a minimal TRS1 dsRNA binding fragment, we
constructed several alanine mutants within the minimal TRS1
dsRBD (Hakki and Geballe, 2005). While the TRS1 dsRBD has no
homology to dsRNA binding proteins found outside of the beta-
herpesviruses, related PKR antagonists from mouse (Child et al.,
2006; Valchanova et al., 2006), rhesus(Child et al., 2012), and
guinea pig (Bierle et al., 2012) CMVs have been shown to bind to
dsRNA. The most conserved portion of these proteins is the US22
domain, which in TRS1 encompasses the minimal dsRNA binding
fragment, residues 74–246. We aligned one known or predicted
TRS1 homologue from each of 13 CMVs (Fig. 6). By comparing with
a second alignment that included the homologues of four addi-
tional US22 family proteins from the same viruses – US22, US23,
US24, and US26 (data not shown) – we identiﬁed four classes of
basic residues, including those (1) unique to human and chim-
panzee TRS1, (2) conserved primarily in TRS1s from primate CMVs,
(3) widely conserved in TRS1 homologues but not in other US22
family proteins, or (4) widely conserved in all US22 family proteins
examined. For this study, we mutated the six residues widely
conserved in TRS1 homologues (R121, R124, K125, R129, R150 and
R162) and two residues conserved only among the TRS1 homo-
logues of primate CMVs (R230 and R245). Because truncation of
TRS1 from TRS1[1–246] to [1–240] resulted in a dramatic loss of
dsRNA binding in previous studies (Hakki and Geballe, 2005), we
also mutated the residues between positions 240 and 246 in the
full length protein.
Rescue of VVΔE3L by TRS1 point mutants
VVΔE3L replicates extremely poorly in most cell types (Beattie
et al., 1996). While E3L interferes with a number of cellular
antiviral pathways (Guerra et al., 2008; Lee and Esteban, 1994;
Liu et al., 2001; Rivas et al., 1998; Smith et al., 2001; Wang et al.,
2008), its replication defect is often attributable to PKR activation,
as evidenced by rescue of viral replication in PKR-deﬁcient cells
(Child et al., 2012; Zhang et al., 2008) or by expression of viral PKR
antagonists such as TRS1 during VVΔE3L infection (Child et al.,
2004). Thus, to evaluate the effects of our mutants on the PKR
pathway, we measured the replication of VVΔE3L in HeLa cells
transfected with mutant TRS1 expression plasmids. As noted
previously, WT TRS1 rescued VVΔE3L replication while EGFP did
not (Fig. 7A) (Bierle et al., 2012; Hakki and Geballe, 2005). A ClaI
site that did not change the TRS1 protein sequence was introduced
into the TRS1 gene to facilitate the construction of TRS1 point
mutants. As expected, this mutation alone did not impact the
ability of TRS1 to rescue VVΔE3L. Most of the point mutants in
single basic amino acids tested only had a modest effect on
VVΔE3L rescue. However, the TRS1[R150A] mutant rescued
VVΔE3L poorly. Of the single amino acid to alanine mutations of
Fig. 6. Conserved basic amino acids in TRS1 homologues. The TRS1 homologues from 13 cytomegaloviruses were aligned using ClustalX2. Above the alignment, basic amino
acids from TRS1 are indicated as either unique to human and chimpanzee CMV (Δ), conserved primarily in primate CMVs ( ), widely conserved in TRS1 homologues but not
other US22 family proteins ( ), or widely conserved in US22 family proteins ( ). Sequences originating from primate viruses are labeled in red (left). The amino acid
position in HCMV TRS1 is indicated below the alignment, and TRS1 residues mutated in this study are indicated by vertical lines (ı, above the sequences). Cytomegaloviruses
originated from rat (R. nor.), mouse (M. mus.), three-striped night monkey (A. tri.), common squirrel monkey (S. sci.), grivet monkey (C. aet.), olive baboon (P. cyn.), rhesus
macaque (M. mul.), crab-eating macaque (M. fas.), common chimpanzee (P. tro.), human (H. sap.), common treeshrew (T. glis), common bent-wing bat (M. sch.), and guinea pig
(C. por.).
Fig. 7. Effects of mutations within the TRS1 dsRNA binding domain on VVΔE3L replication. HeLa cells were transfected with the indicated TRS1 mutants and infected with
VVΔE3L 24 h later. Viral replication was measured at 24 h post infection and the expression of the transfected proteins was measured by α-His immunoblot. Full-length TRS1
is indicated, while (n) indicates a frequently observed TRS1 fragment. Triple is TRS1[R121A/R124A/ K125 A]; Quad is TRS1[G241A/E242A/V243A/R245A].
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to WT TRS1 and E242A, V243A, and R245A reduced VVΔE3L
replication partially, while TRS1[G241A] most severely limited
VVΔE3L rescue (Fig. 7B and data not shown).
Based on analyses of these point mutants, we constructed two
multi-residue mutants. A triple mutant (TRS1[R121A/R124A/ K125A])
of a conserved cluster of basic residues resulted in marked reductionin the ability of TRS1 to rescue VVΔE3L (Fig. 7A). Likewise, a quadruple
mutant (TRS1[G241A/E242A/V243A/R245A]) was severely deﬁcient in
rescuing VVΔE3L replication (Fig. 7B). Analyses of the expression of
the transfected genes by anti-His blotting revealed the full length TRS1
proteins and a smaller immunoreactive band, similar to one found in
other experiments (Fig. 4 and (Hakki and Geballe, 2005)), which we
suspect is a degradation product. Regardless, the level of expression of
C.J. Bierle et al. / Virology 442 (2013) 28–37 33the various mutants could not account for the observed differences in
their ability to rescue VVΔE3L.
Binding of TRS1 mutants to dsRNA and PKR.
Next, we investigated whether the impact of these TRS1
mutants on VVΔE3L replication might be explained by defects in
their ability to bind to dsRNA or to PKR. To evaluate dsRNA
binding, we transfected Cos7 cells with mutant TRS1 expression
plasmids, lysed the cells, incubated the lysates with control or poly
(I:C) beads, and detected the bound proteins by anti-His immuno-
blot assay. Representative blots are shown in Fig. 8. We compared
the binding of TRS1 point mutants to wildtype TRS1 and TRS1
[Δ86–246], a mutant wherein the dsRNA binding domain has been
deleted (Hakki and Geballe, 2005). Although a few mutants (e.g.
R245A) bound to poly(I:C) beads similarly to WT TRS1, most
seemed to bind only weakly. R150A, G241A, the triple mutant,
and the quadruple mutant did not bind dsRNA at all in this or
other experiments, including ones (not shown) in which the
expression of G241A and the quadruple mutant was more similar
to that of the other mutants. These results support the conclusion
that at least weak dsRNA binding by TRS1 is necessary for its
function as a PKR antagonist.
To assess the ability of these mutants to bind to PKR, we
contransfected the His-tagged TRS1 mutants along with plasmids
expressing kinase-dead PKR with a biotinylation signal in addition
to the 6XHis tag and a separate plasmid expressing biotin ligase.
Following cell lysis, biotin-tagged PKR, along with any associated
TRS1, was pulled down using avidin beads and both PKR and TRS1
mutants were detected by anti-His immunoblot (Fig. 9). As
expected, WT TRS1 bound to PKR and the C-terminal deletion
mutant TRS1(1–648) did not bind (Hakki et al., 2006). Most of theFig. 8. dsRNA binding by TRS1 point mutants. HeLa cells were transfected with the
indicated TRS1 mutants, lysed, and the lysates bound to naked (data not shown) or
poly I:C agarose beads. dsRNA bound protein, along with input protein equal to 10%
of the amount used in binding reactions, was separated by SDS-PAGE and
visualized by α-His immunoblot. Two exposures of the immunoblot are shown to
best differentiate strong versus weak versus non-binders.
Fig. 9. PKR binding by TRS1 point mutants. Cos7 cells were transfected with plasmids th
tagged TRS1 mutants. Biotinylated PKR and any associated proteins were pulled down
following SDS-PAGE, and the bands that correspond to TRS1 and PKR are indicated.mutants tested bound to PKR. The only exception was the quad-
ruple mutant which expressed poorly in this experiment. Notably,
R150A and the triple mutant bound to PKR even though they were
deﬁcient in binding to dsRNA and in rescuing VVΔE3L replication.
These results indicated that dsRNA and PKR binding are separable
functions of TRS1 and that PKR binding by TRS1 is not sufﬁcient for
its ability to block the PKR pathway.Discussion
PKR is activated by dsRNA that accumulates during viral
infection and has the potential to inhibit formation of the
eIF2–tRNAiMet–GTP ternary complex and translation initiation.
Most viruses must block the PKR pathway to replicate, and HCMV
is no exception. A HCMV mutant that lacks its PKR antagonists,
TRS1 and IRS1, is unable to replicate in normal ﬁbroblasts
(Marshall et al., 2009). While previous studies have suggested
that interactions with dsRNA (Hakki and Geballe, 2005) and PKR
(Hakki et al., 2006) may be necessary for TRS1 to block the PKR
pathway, we have little insight into structural basis for TRS1's
interaction with its binding partners nor do we completely under-
stand the roles of these interactions in TRS1's ability to function as
a PKR antagonist. Nonetheless, dsRNA binding is a conserved
function of the PKR antagonists of human (Marshall et al., 2009),
mouse (Budt et al., 2009), rhesus (Child et al., 2012), and guinea
pig cytomegaloviruses (Bierle et al., 2012) and thus seems likely to
be key to its function.
Like TRS1, other viral PKR antagonists have been identiﬁed that
bind to both dsRNA and to PKR. The relative importance of these
interactions for the inhibition of PKR varies. For example, the
N-terminal E3L PKR-binding domain is not essential to block PKR
or for VV replication in cell culture, suggesting that E3L may be
able to function simply by sequestering dsRNA (Shors et al., 1997).
However, E3L lacking this PKR-binding domain cannot block the
inhibitory effects of PKR in a yeast growth assay nor does it fully
prevent PKR pathway activation at late times in infection
(Langland and Jacobs, 2004; Romano et al., 1998). Furthermore,
VV with this deletion is not virulent in mice, though whether that
phenotype is related to PKR antagonism is unknown (White and
Jacobs, 2012). Overall, it seems that dsRNA binding by E3L in the
absence of PKR-binding enables VV replication in some experi-
mental contexts. In contrast to E3L, which binds to dsRNA with an
afﬁnity similar to that of PKR (Ho and Shuman, 1996), the
inﬂuenza PKR antagonist NS1 binds to dsRNA very weakly using
a noncanonical dsRBD (Chien et al., 2004). Because it cannot
effectively compete with PKR for dsRNA binding, it is unable to
sequester dsRNA and must block the pathway by directly binding
to PKR (Li et al., 2006; Shors et al., 1997).at expressed biotin ligase, biotin signal and 6XHis-tagged, kinase dead PKR, and His
with avidin agarose following lysis. Proteins were detected by α-His immunoblot
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function. It could bind to and sequester dsRNA away from PKR, or
could inhibit PKR primarily by binding to and preventing the
activation of PKR. Alternatively, both interactions may be necessary,
suggesting that TRS1 complexes simultaneously with both PKR and
dsRNA to inhibit PKR activation. In this study, we sought to clarify
which of these models most accurately represents how TRS1
functions by better characterizing TRS1's dsRNA binding activity.
Expressing and purifying TRS1 from a baculovirus vector
enabled more detailed investigations of its dsRNA binding than
previously possible. For example, we were able to show that TRS1
binds to dsRNA in the absence of other proteins (Fig. 1). Notably,
TRS1 binds to dsRNAs even shorter than the 30 bp that are needed
to bind to and activate PKR (Manche et al., 1992). Our ﬁnding that
TRS1 can bind to dsRNA as short as 20 bps raises the possibility
that it might participate somehow in microRNA metabolism,
though we have been unable to detect any effects of TRS1
expression on RNAi-mediated silencing (data not shown).
Our data indicate that TRS1 binds to dsRNA less avidly than PKR
and thus would be unlikely to compete with an equimolar amount
of PKR for binding to free dsRNA. The relatively high abundance of
TRS1 compared to PKR when dsRNA is detectable in infection
(Fig. 4) could offset the competitive disadvantage of TRS1 for dsRNA
binding. However, our ﬁnding that mutants of TRS1 with impaired
dsRNA binding compared to WT TRS1 are nonetheless still able to
rescue VVΔE3L replication (Figs. 7 and 8) suggests that TRS1 does
not block PKR activation simply by sequestering free dsRNA.
Although efﬁcient dsRNA binding does not appear to be essential
for TRS1 to rescue VVΔE3L, our data also suggest that a minimal
level of binding may be necessary. TRS1 mutants that were most
deﬁcient in biding to dsRNA were also the least able to rescue
VVΔE3L replication. Interestingly, the triple mutant and TRS1
[R150A] still bound to PKR, revealing that TRS1 binding to PKR
and to dsRNA are genetically separable and that binding to PKR is
not sufﬁcient to rescue VVΔE3L replication. However, our PKR-
binding assays were not quantitative and it remains possible that at
least weak binding to dsRNA is needed to stabilize the interaction
between TRS1 and PKR in cells. Overall, our data are most consistent
with a model similar to what has been proposed for other viral PKR
antagonists in which TRS1 binds to PKR and to dsRNA simulta-
neously, through different domains, and prevents PKR homodimer-
ization and activation (Dever et al., 2007; Langland et al., 2006). We
expect that further characterization of the TRS1–PKR structural
interface will help to evaluate the validity of this model.
TRS1, like many other viral proteins, is multifunctional. In
addition to binding dsRNA and antagonizing PKR, TRS1 has been
reported to play a role in viral transcription (Stasiak and Mocarski,
1992), virion packaging (Adamo et al., 2004), inhibition of autop-
hagy (Chaumorcel et al., 2012), and inhibition of the 2′-5′ oligoa-
denylate synthetase/RNase L pathway (Child et al., 2004). As well,
TRS1 and IRS1 bind to HCMV DNA replication proteins and IRS1
has been recently shown to bind to the HCMV lytic origin of
replication (Kagele et al., 2012; Strang et al., 2010). While PKR is
activated by infection with HCMV[ΔI/ΔT], we do not yet know
which TRS1 and IRS1 functions are the essential one(s). Further
analyses of precise mutations of TRS1 such as ones reported here
will be valuable for clarifying which TRS1 interactions and func-
tions are critical for HCMV replication.Materials and methods
Cells and virus
Human ﬁbroblasts (HFs), COS-7 (ATCC CRL-1651), and HeLa
cells were propagated on Dulbecco's modiﬁed Eagle's mediumsupplemented with 10% NuSerum (BD Biosciences) as previously
described (Child et al., 2004). SF9 cells (from Bruce Clurman,
FHCRC) were propagated either in Grace's Insect Media (Invitro-
gen) supplemented with 10% fetal bovine serum or in SF-900 III
(Invitrogen). VVΔE3L was obtained from Bertram Jacobs and
propagated and titered in BHK cells (Beattie et al., 1995; Child
et al., 2004). HCMV[AD169] (ATCC, VR-538) and HCMV[Towne]
(ATCC, VR-977) were propagated and titered on HFs.
Plasmids
pEQ1257 was cloned by digesting pEQ1180 (Child et al., 2012)
with BamHI and PmeI and ligated into pFastBac Dual (Invitrogen)
that was digested with BamHI and StuI. pEQ1258 was cloned by
digesting pEQ1236 (pUC57 containing yeast codon optimized TRS1
[GenScript]) with EcoRI and PstI and cloned into pFastBac Dual
linearized with EcoRI and PstI.
pEQ1196 was cloned by amplifying pEQ1180 with PCR primers #88
(5′-AGGCGTGTACGGTGGGAGGTCTAT-3′) and #695 (5′-ACGCC-
CAGCCGGTTGCATCGATACACCCGCACCACCT-3′) with Phusion polymer-
ase (New England Biolabs). The resulting fragment was cut with
HindIII and ligated into pEQ1180 that had been linearized with
HindIII and PmlI to generate pEQ1195. A second PCR reaction product
resulting from ampliﬁcation of pEQ1180 using primers #652
(5′-TAGAAGGCACAGTCGAGG-3′) and #694 (5′-AGGTGGTGCGGGTG-
TATCGATGCAACCGGCTGGGCGT-3′) was digested with BsrG1 and ClaI
and ligated into pEQ1195 that had been linearized with the same
enzymes. pEQ1209 was cloned by ampliﬁcation of pEQ1180
with primers #88 and #720 (5′-TTGCATCGATACACCCGCAC-
CACCTCGGGCGCGCCGTGCCGAAACCA-3′). The resulting PCR product
was digested with HindIII and ClaI and ligated into pEQ1196 that had
been linearized with the same enzymes. This introduced an AseI
restriction site and a [G241P] mutation into the TRS1 gene.
TRS1 point mutants were cloned by digesting pEQ1209 with
AseI and ClaI and ligating in the following annealed primer pairs:
pEQ1216 (TRS1[G241A], #725, 5′-CGCGGCGGAGGTGGTGCGGGTG-
TAT-3′ and #726, 5′-CGATACACCCGCACCACCTCCGC-3′); pEQ1217
(TRS1[E242A], #727, 5′-CGCGGGCGCGGTGGTGCGGGTGTAT-3′ and
#728, 5′-CGATACACCCGCACCACCGCGCC-3′); pEQ1220 (TRS1
[R245A], #731, 5′-CGCGGGCGAGGTGGTGGCGGTGTAT-3′ and #732,
5′-CGATACACCGCCACCACCTCGCC-3′); pEQ1223 (TRS1[V243A],
#736, 5′-CGCGGGCGAGGCGGTGCGGGTGTAT-3′ and #737, 5′-CGA-
TACACCCGCACCGCCTCGCC-3′); pEQ1224 (TRS1[V244A], #738, 5′-
CGCGGGCGAGGTGGCGCGGGTGTAT-3′ and #739, 5′-CGATA-
CACCCGCGCCACCTCGCC-3′); pEQ1225 (TRS1[V246A], #740, 5′-
CGCGGGCGAGGTGGTGCGGGCGTAT-3′ and #741, 5′-CGATACGCCCG-
CACCACCTCGCC-3′); and pEQ1370 (TRS1[G241A/E242A/V243A/
R245A], #929, 5′-CGCGGCTGCCGCTGTGGCCGTGTAT-3′ and #930,
5′-CGATACACGGCCACAGCGGCAGC-3′).
Additional TRS1 point mutants were cloned by stitch PCR using
precisely complementary forward and reverse primer pairs along with
Phusion polymerase. For the ﬁrst set of PCR reactions, oligonucleotide
#88 was combined with each reverse primer while primer #450 (5′-
CACCGCGCCCAGCGCCAGCCA-3′) was combined with each forward
primer using pEQ1196 as a template. PCR products were puriﬁed using
Geneclean II (MP Bio) and used for a second round of PCR where the
products for each matching set of reactions were combined and
ampliﬁed with primers #88 and #450. The ﬁnal stitch PCR products
were digested with HindIII and ClaI and ligated into pEQ1196 that had
been linearized with the same enzymes. This protocol was used to
clone the following plasmids (only the forward primers are shown):
pEQ1424 (TRS1[R121A]; 5′ CCAACAGCACGGGCGCCGCCATGCGCAAG
3′); pEQ1425 (TRS1[R124A]: 5′-CGGGCCGCGCCATGGCCAAGTGGTCG-
CAGCG-3′); pEQ1426 (TRS1[K125A]: 5′-GCCGCGCCATGCGCGCGT
GGTCGCAGCGCG-3′); pEQ1427 (TRS1[R121A/R124A/ K125A]: 5′-
CCAACAGCACGGGCGCCGCCATGGCCGCGTGGTCGCAGCGCG-3′);
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CACGC-3′); pEQ1429 (TRS1[R150A]: 5′-CGCGGGTGACGCCGGCCAGC-
CAGATGAACGGC-3′); pEQ1430 (TRS1[R162A]: 5′-GCGCGACGGACCT
GGCGCAGCTGTCGCCGCG-3′); and pEQ1431 (TRS1[R230A]: 5′-
GATCCTGGCGGCGGCCGACGCGGACGAGTG-3′).HCMV infections
HFs were infected with HCMV (Towne or AD169) at a MOI of
3 PFU/cell by diluting virus into medium, allowing adsorbtion for
2 h, and replacing the inoculum with fresh medium. Mock or
HCMV infected cells were harvested by lysis with 2% SDS prior to
immunoblotting.Construction of recombinant baculovirus
Competent DH10Bac cells (Invitrogen), prepared using the
calcium chloride method (Hewitt and McDonnell, 2004), were
transformed with pFastBac Dual, pEQ1257, and pEQ1258 and
grown on LB agar plates containing kanamycin (50 ug/ml), genta-
micin (7 ug/ml), tetracycline (10 ug/ml), X-Gal (40 ug/ml), and
IPTG (40 ug/ml). Recombinant bacmid containing colonies were
picked and bacmid DNA was isolated using the Invitrogen's Bac to
Bac protocol. SF9 cells were transfected with bacmid DNA using
Lippofectamine 2000. The media from the transfection was har-
vested 8 days later and used to infect SF9 cells. Virus containing
media was harvested at 72 h post infection and titered on SF9 cells
according to Invitrogen's instruction. Subsequent baculovirus pas-
sages were propagated in SF9 cells following infections at a MOI of
0.1–0.5 and virus containing media was harvested at 72 h post
infection.Puriﬁcation of TRS1 from insect cells
Conﬂuent SF9 cells were infected with BVEQ1266 at a MOI of
0.5. At 72 h post infection, cells were sloughed off of the plate,
pelleted at 500  g, and washed with PBS. After pelleting again,
the cells were lysed in buffer containing 500 mM NaCl, 50 mM
sodium phosphate pH 7.0, 1% NP-40, and 20 mM imidazole by
incubating for 15 min on ice. The lysate was then clariﬁed by
centrifugation at 15800  g. After washing in lysis buffer,
PerfectPro NiNTA agarose or superﬂow (5Prime) beads were added
to the clariﬁed lysate and incubated for 2 h at 4 1C with rotation.
The beads were then pelleted at 500  g, then washed with
buffer, containing 500 mM NaCl, 50 mM sodium phosphate pH 7.0,
1% NP-40, and 50 mM imidazole, by incubating at 4 1C with
rotation for 15 min before transferring to a centrifuge column
(Pierce) and centrifuging at 500  g. After four washes, the TRS1
was collected after incubating the beads in elution buffer 1
(500 mM NaCl, 50 mM sodium phosphate pH 7.0, and 100 mM
imidazole) for 5 min at 4 1C with rotation, and centrifugation at
500  g. This step was repeated once more with elution buffer 1,
and twice with elution buffer 2 (500 mM NaCl, 50 mM sodium
phosphate pH 7.0, and 250 mM imidazole). Final protein concen-
trations were determined by measuring absorbance at 280 nm
using the Nanodrop 2000 and by the ﬂuoraldehyde o-phthalalde-
hyde (OPA, Pierce) assay (Geballe and Mocarski, 1988).Preparation of PKR
PKR was expressed and puriﬁed from bacteria as previously
described (Conn, 2003). Protein concentrations were determined
by either the Bradford or OPA assay.dsRNA binding assay
dsRNA [poly I:C] agarose beads were prepared as described
previously (Langlan et al., 1995). Puriﬁed protein was directly added
to Buffer A (Hakki and Geballe, 2005). Transfected cells were
trypsinized, pelleted at 500  g for 5 min, washed once with PBS,
then lysed by incubating in Buffer A for 20 min on ice, after which
the nuclei were pelleted by centrifuging (16,000  g) for 15 min at
4 1C. The samples were split between a mixture of 10% dsRNA
agarose beads in carrier Sepharose CL‐6B (Sigma‐Aldrich) or with
control Sepharose CL‐6B alone and incubated for 2 h at 4 1C on a
rotating mixer. After binding, the beads were pelleted (845  g,
3 min) and washed in Buffer A 3–4 times, after which the bound
proteins were denatured, separated on 10% SDS-PAGE gels and
visualized either by coomassie staining or immunoblotting.
Electrophoretic mobility shift assay
The following oligonucleotides were annealed and transcribed
in vitro (MAXIscript, Ambion), labeling with α-32P -UTP (EasyTides,
Perkin-Elmer), according to the manufacturer's instructions, to
synthesize hairpin dsRNAs: #675 (5′-TAATACGACTCACTATAG-3′)
and #807 (5′-GGGCGAAUUGGAGCUCCACCGCGGUGGCGGCCGCU-
CUAGAGGACUAGAGCGGCCGCCACCGCGGUGGAGCUCCAAUUCGCCC-
3′), #675 and #890 (5′- GGGCGAAUUGGAGCUCCACCGCGGUGGC-
GAGGACGCCACCGCGGUGGAGCUCCAAUUCGCCC-3′), #675 and 3891
(5′- GGGCGAAUUGGAGCUCCACCAGGAGGUGGAGCUCCAAUUCGCCC-
3′). The concentrations of hairpin RNA were calculated using the
LS 6500 scintillation counter (Beckman Coulter). For binding reac-
tions, between 0.25 and 1 pmol of hairpin RNA was incubated in
EMSA buffer (325 mM NaCl, 32.5 mM sodium phosphate (pH 7.0),
162.5 mM imidazole, 0.1 mg/μl sonicated salmon sperm DNA, 0.2 mg/
μl BSA, 0.2% Triton X-100, and 2 mM DTT) with TRS1 or PKR at ﬁnal
concentrations between 3.2 and 1000 nM at room temperature for
15 min. For competition experiments, 2 ng of 29 bp hairpin was
incubated as described above with 320 nM TRS1. Between 2 and
63 ng of Poly I:C, Poly C, or tRNAwas added to each binding reaction.
3X loading buffer (325 mM NaCl, 32.5 mM sodium phosphate (pH
7.0), 163 mM imidazole, 0.2% Triton X-100, 2 mM DTT, and 15%
glycerol) with dye was added to the binding reactions and separated
10% Mini-PROTEAN TBE Precast Gels (Bio-RAD) with 0.5X TBE. Gels
were dried and visualized by phosphorimager analysis (Typhoon Trio
[GE Healthcare]) and bands quantiﬁed using the ImageQuant soft-
ware. The fraction of the RNA probe bound compared to the
remaining unbound probe at each protein concentration was plotted
and the dissociation concentration was calculated using nonlinear
least-squares ﬁt to Eq. (3) from Ryder et al., (2008) using GraphPad
Prism 6 software.
HPG modiﬁcation of TRS1
PKR or TRS1 was modiﬁed with p-hydroxyphenylglyoxal (HPG,
Thermo) either before or after binding to poly I:C agarose beads.
Puriﬁed protein or protein bound to poly I:C beads as described
above was incubated in HPG buffer (50 mM Hepes, pH 8, 50 mM
boric acid, 150 mM NaCl) containing between 1 and 50 mM of HPG
(McKee et al., 2009) for 1 h on a rotator in the dark at 37 1C. For the
dsRNA bound samples, arginine was added to a ﬁnal concentration
of 10 mM. The beads were pelleted at 16,000  g for 5 min, and
washed once more with buffer A prior to SDS-PAGE. For puriﬁed
proteins modiﬁed with HPG, modiﬁed TRS1 or PKR was concen-
trated using an Amicon Ultra 0.5 Filter (10,000 kDa, Millipore) by
centrifugation at 16,000  g for 5 min. Buffer A was added to the
proteins, which were centrifuged 16,000  g for 20 min before
subjecting the samples to the dsRNA binding assay.
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US22 genes, including the known or predicted TRS1 homo-
logues, from human herpesvirus 6A (NC_001664.2) and cytome-
galoviruses that originated from the following mammals were
aligned using ClustalX2: rat (R. nor., NC_002512.2), mouse (M.
mus., NC_004065.1), three-striped night monkey (A. tri., FJ483970),
common squirrel monkey (S. sci., FJ483967), grivet monkey (C. aet.,
FJ483969), olive baboon (P. cyn. AC090446.27), rhesus macaque
(M. mul., NC_006150.1), crab-eating macaque (M. fas., JN227533),
common chimpanzee (P. tro., NC_003521.1), human (H. sap.,
NC_006273), common treeshrew (T. glis, NC_002794.1), common
bent-wing bat (M. sch., JQ805139), and guinea pig (C. por.,
NC_011587.1)
VVΔE3L rescue
Triplicate wells of subconﬂuent HeLa cells were transfected
with the indicated plasmid using Lipofectamine 2000 (Invitrogen)
according to the manufacturer's instructions. 24 h post transfec-
tion, cells were infected with VVΔE3L at a MOI of 1 or 5 and viral
replication was quantiﬁed using four methylumbelliferyl β-D-
galactopyranoside (MUG) at 24 h post infection (Hakki and
Geballe, 2005). In previous studies, we have veriﬁed that
β-galactosidase expression from the lacZ cassette in VVΔE3L
correlates well with viral titers (Child et al., 2002; Elde et al.,
2012).
PKR binding assay
Subconﬂuent COS-7 cells in 6 well plates were transfected
using Lipofectamine 2000 with a mixture of 1.3 mg of each of three
plasmids: (1) pCS2+BirA (Child and Geballe, 2009) (2) Bio/His-
tagged, kinase-dead PKR (pEQ1068) and (3) a plasmid expressing
6X-His-tagged TRS1 variants or GFP. Biotinylated PKR and asso-
ciated proteins were pulled-down as previously described (Bierle
et al., 2012) and detected by α-His immunoblot.
Immunoblot analyses
Unless otherwise noted, cells were lysed with 2% SDS. Cellular
DNA was sheared with a Bransonic bath sonicator and protein
concentrations were determined using ﬂuoraldehyde o-phthalal-
dehyde (OPA, Pierce) assay (Geballe and Mocarski, 1988). Equiva-
lent amounts of protein from lysed cells or deﬁned quantities of
puriﬁed proteins were separated by SDS-PAGE prior to transfer to
polyvinylidene diﬂuoride membranes (GE Life Sciences) by elec-
troblotting. Proteins were detected using the Western‐Star™
chemiluminescent detection system (Applied Biosystems) accord-
ing to the manufacturer's instructions using a 1:5000 dilution of
α-TRS1 (αp999) (Marshall et al., 2009) or using the following
commercial primary antibodies diluted 1:1000: Actin (Sigma
A-2066), Penta‐His (Qiagen, 34660), PKR (Santa Cruz Biotechnol-
ogy, Inc. sc‐6282 and sc-707; R&D systems, clone #HL71/10),Acknowledgments
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